ERBB2 and anaplastic large cell lymphoma: For instance, two of the ADCs approved for cancer therapy, which employ microtubule-disrupting agents (auristatins and maytansines) as their payload, are brentuximab vedotin for the treatment of anaplastic large cell lymphoma (ALCL) and T-DM1 for use in HER2-positive breast cancer [23–25].